INTRODUCTION
============

Mutations in the DNA molecule are the basis of evolution. It is widely accepted that tautomerism of the canonical nucleobases and the formation of wobble base pairs play an important role in this phenomenon ([@b1],[@b2]). To keep the number of errors low, enzymatic proof reading during nucleoside triphosphates incorporation takes place with the help of polymerases ([@b3]). DNA mutation is caused by mismatches of the normal bases because of a failure of proofreading during DNA replication ([@b4]). DNA is also damaged continuously by oxidation, by depurination, by light or other processes occurring within the cellular environment. The daily number of errors in a human is estimated to be several thousands. This damage is removed by repair enzymes ([@b5]).

Several diagnostic tools have been developed to detect such single nucleotide polymorphisms (SNPs) by hybridization in solution or on polymer surfaces (biochips). Modified nucleosides are used in these protocols as fluorescent dyes to be anchored to them without disturbing the DNA structure ([@b6],[@b7]). 7-Deazapurine nucleoside triphosphates are commonly used for these purposes ([@b6]--[@b8]). Thus, the knowledge about their recognition properties and base discrimination is of mutual interest. Mismatch discrimination is evaluated from the difference in melting temperatures (*T*~m~) between matched and mismatched base pairs within an oligonucleotide duplex. For a given mismatch, the properties of the modified nucleosides incorporated in the DNA chain and the environmental conditions are of utmost importance for the stability of base pairs. Although studies on the mispairing of modified nucleosides have been performed, little attention has been paid to the influence of the pH values of the reaction medium on the recognition of canonical and modified nucleosides.

Among the modified nucleosides, 7-deazapurine (pyrrolo\[2,3-*d*\]pyrimidine) nucleosides and 7-substituted derivatives (purine numbering is used throughout the discussion) have attracted attention because they closely resemble the structure of purine nucleosides and are therefore ideal shape mimics of the canonical DNA constituents. They are well accepted by DNA polymerases and made a significant contribution to DNA and RNA sequencing and diagnostics ([@b6]--[@b9]). Reporter groups that are necessary to generate high-sensitivity probes are usually introduced at the 7-position of a 7-deazapurine giving them steric freedom in duplex DNA. Substituents of moderate size incorporated into the DNA chain have shown to increase duplex stability with the potential of a better mismatch discrimination ([@b10]--[@b14]).

2′-Deoxytubercidin (**1a**) and its 2-amino derivative **2a** can substitute 2′-deoxyadenosine (dA) without significantly changing the base pair stability with dT ([@b15],[@b16]) (see also Table 2). Studies on the p*K*~a~ values of 7-deazapurine nucleosides show that compared to the parent dA (p*K*~a~ = 3.50) ([@b17]) compounds **1a** (p*K*~a~ = 5.30) ([@b18]) and **2a** (p*K*~a~ = 5.71; Supplementary Data) are much more easily protonated. Moreover, it is shown that the p*K*~a~ values of nucleobases present in stacked oligonucleotides can be significantly higher due to the attractive force of the phosphodiester backbone for the protons ([@b17]). Thus, the p*K*~a~ values of nucleobases are shifted by one or two p*K*~a~ units towards neutral conditions. This indicates that 7-deazaadenine nucleosides such as **1a** or **2a** as constituents of oligonucleosides might be protonated already under neutral conditions. In order to investigate this matter in more detail, 2′-deoxytubercidin (**1a**) as well as 2-, or 7-substituted derivatives (**1d**, **2a**--**d**, **3**) or **4** were incorporated into oligonucleotides and their hybridization properties were studied ([Scheme 1](#sch1){ref-type="fig"}). For this, the phosphoramidites (**5a**--**d** and **6**) were synthesized and the base pair stability as well as the pH-dependent mismatch discrimination of oligonucleotides were investigated.

MATERIALS AND METHODS
=====================

General
-------

All chemicals were purchased from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany). Solvents were of laboratory grade. Snake-venom phosphodiesterase (EC 3.1.15.1, *Crotallus adamanteus*) and alkaline phosphatase (EC 3.1.3.1, *Escherichia coli*) were gifts from Roche Diagnostics GmbH (Germany). The phosphoramidites related to compounds **1a**, **1d** and **4** were synthesized as described previously: 4-benzoylamino-7-\[2-deoxy-5-*O*-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-*erythro*-pentofuranosyl\]-7*H*-pyrrolo\[2,3-*d*\]pyrimidine 3′-(2-cyanoethyl)-*N,N*-diisopropylphosphoramidite ([@b19]), 7-\[2-deoxy-5-*O*-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-*erythro*-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-5-iodo-7*H*-pyrrolo\[2,3-*d*\]pyrimidine 3′-(2-cyanoethyl)-*N,N*-diisopropylphosphoramidite ([@b20]) and 7-\[2-deoxy-5-*O*-(4,4′-dimethoxytriphenylmethyl)-β-D-*erythro*-pentofuranosyl\]-2-formylamino-7*H*-pyrrolo\[2,3-*d*\]pyrimidine 3′-(2-cyanoethyl)-*N,N*-diisopropylphosphoramidite ([@b21]). The standard phosphoramidites are commercial materials bought from Proligo (Hamburg, Germany). Thin-layer chromatography (TLC) was performed on TLC aluminium sheets covered with silica gel 60 F~254~ (0.2 mm, VWR International, Darmstadt, Germany). Column flash chromatography (FC): silica gel 60 (VWR International, Darmstadt, Germany) at 0.4 bar. UV Spectra were recorded on a U-3200 spectrophotometer (Hitachi, Japan). NMR spectra were measured on an Avance-250 or AMX-500 spectrometers (Bruker, Rheinstetten, Germany). Chemical shifts (δ) are given in p.p.m. relative to internal Me~4~Si or external H~3~PO~4~ (^31^P). The *J*-values are given in Hz. Elemental analyses were performed by the Mikroanalytisches Laboratorium Beller, Göttingen, Germany.

Oligodeoxyribonucleotides
-------------------------

The oligonucleotide synthesis was performed on an ABI 392-08 synthesizer (Applied Biosystems, Weiterstadt, Germany) on a 1.0 μmol scale using the phosphoramidites **5a**--**d**, **6** as well as those of the canonical 2′-deoxyribonucleosides (Proligo, Hamburg, Germany) following the synthesis protocol for 3′-cyanoethyl phosphoramidite chemistry ([@b22]). The phosphoramidites related to compounds **1a** ([@b19]), **1d** ([@b20]) and **4** ([@b21]) were also employed. The average coupling yield of the modified phosphoramidites was always \>98%. After cleavage from the solid-support, the oligonucleotides were deprotected in 25% aq. NH~3~ for 16--18 h at 60°C. The synthesis of oligonucleotides incorporating the 2-fluoro nucleoside **3** used ^t^BPA-protected (*tert*-butylphenoxyacetyl) canonical phosphoramidites and employing ultra mild deprotection conditions (25% aq. NH~3~, room temperature, 2 h). If the deprotection was performed at elevated temperature (25% aq. NH~3~, 60°C, 20--24 h), the 2-fluoro substituent was displaced by an amino group. This conversion can be used to synthesize oligonucleotides containing the diamino nucleoside **2a** using the 'fluoro' phosphoramidite **6** instead of **5a**. The oligonucleotides were purified by reversed-phase HPLC. The detailed procedure for oligonucleotide purification is shown in Supplementary Data.

The compositions of oligonucleotides was determined by reversed-phase HPLC (RP-18) after tandem enzymatic hydrolysis with snake-venom phosphodiesterase (EC 3.1.15.1, *C.adamanteus*) followed by alkaline phosphatase (EC 3.1.3.1, *E.coli* from Roche Diagnostics GmbH, Germany) ([@b11]) (Supplementary Data). The absorbances were quantified at 260 nm by measuring the peak areas under consideration of the molar extinction coefficient of each monomer. Quantification of the material was made as shown in ([@b11],[@b14]). These data fit with the calculated data, which shows that the oligonucleotides were completely hydrolyzed. The molecular masses of all synthesized oligonucleotides were determined by MALDI-TOF mass spectra measured on a Biflex-III spectrometer in the reflector mode (Bruker Saxonia, Leipzig, Germany). They were in agreement with the calculated values. A table of MALDI-TOF mass data for characterization is shown in Supplementary Data.

UV thermal denaturation curves were acquired on a *Cary-1/3* UV/VIS spectrophotometer (Varian, Australia) equipped with a Cary thermoelectrical controller. All thermal measurements were conducted in 0.1 M NaCl, 10 mM MgCl~2~ and 10 mM sodium cacodylate buffer, with 5 μM single-strand concentration. The extinction coefficients at 260 nm of oligonucleotides were calculated from the sum of the extinction coefficients of the monomeric 2′-deoxyribonucleosides corrected by the hypochromicity. The hypochromicity (*h* = \[(ɛ~monomer~ − ɛ~polymer~) × (ɛ~monomer~)^−1^\] × 100%) was determined from the absorbance before and after enzymatic digestion with snake-venom phosphodiesterase (EC 3.1.15.1, *C.adamanteus*) \[for details see ([@b11])\]. The hypochromicity was ∼20% for all oligonucleotides (ɛ~260~ of monomers: Cl^7^c^7^iG~d~ 6350, dA 15400, dT 8800, dG 11700, dC 7600, m^5^iC~d~ 6300, **2a** 8100, **2b** 8200, **2c** 7700, **2d** 7800, **3** 9800, **4** 4100). Absorbance versus temperature spectra were collected at 260 nm over a range of 10--85°C with 0.1°C increments and a heating rate of 1.0°C/min. Samples were annealed by heating rapidly to 85°C for 10--15 min, followed by cooling slowly to 10°C. The thermodynamic data were calculated with the program Meltwin 3.0 ([@b23]).

*7-(2-Deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-4-\[(dimethylamino) methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****7a***). A solution of 7-(2-deoxy-β-[d]{.smallcaps}-*erythro*-pentofuranosyl)-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-2,4-diamine (**2a**) ([@b24]) (400 mg, 1.51 mmol) in MeOH (15 ml) was stirred with *N*,*N*-dimethylformamide dimethylacetal (2.0 ml, 14.9 mmol) for 24 h at 40--50°C. After removal of the solvent, the residue was redissolved in MeOH (20 ml) and two drops of water were added. The solution was stirred at 30--40°C for 48 h and adsorbed on a small amount (5.0 g) of silica gel. This material was loaded on the top of a silica gel column (4 × 10 cm), and the product was eluted stepwise with CH~2~Cl~2~/MeOH (98:2, 300 ml) and CH~2~Cl~2~/MeOH (95:5, 600 ml). The product-containing fractions were combined and evaporated to give a colorless foam (390 mg, 74%). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.33. UV (MeOH): λ~max~ = 233, 271, 325 nm (ɛ = 20 100, 15 000, 8000). ^1^H NMR (DMSO-*d*~6~): δ = 2.11--2.17, 2.42--2.50 \[2m, 2 H, H-C(2′)\]; 3.11, 3.18 (2s, 6 H, Me~2~N); 3.48--3.54 \[m, 2 H, H-C(5′)\]; 3.76 3.80 \[m, 1 H, H-C(4′)\]; 4.31--4.34 \[m, 1 H, H-C(3′)\]; 4.91 \['t', 1 H, *J* = 5.3 Hz, OH-C(5′)\]; 5.28 \[d, 1 H, *J* = 3.6 Hz, OH-C(3′)\]; 6.46--6.51 \[m, 2 H, H-C(5), H-C(1′)\]; 7.33 \[d, 1 H, *J* = 3.6 Hz, H-C(6)\]; 8.83 (s, 1 H, N=CH); 9.48 (d, 1 H, *J* = 9.9 Hz, NH); 10.39 (d, *J* = 9.9 Hz, 1 H, COH). Anal. calc. for C~15~H~20~N~6~O~4~ (348.36): C, 51.72; H, 5.79; N, 24.12; found: C, 51.72; H, 5.70; N, 23.95.

*5-Chloro-7-(2-deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****7b***). Compound **7b** was prepared from 5-chloro-7-(2-deoxy-β-[d]{.smallcaps}-*erythro*-pentofuranosyl)-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-2,4-diamine (**2b**) ([@b25]) (500 mg, 1.67 mmol) and *N,N*-dimethylformamide dimethylacetal (3.0 ml, 22.4 mmol) as described for **7a**. FC (silica gel, column 4 × 10 cm, elution with CH~2~Cl~2~/MeOH, 95:5) resulted in a colorless foam (518 mg, 81%). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.33. UV (MeOH): λ~max~ = 234, 272, 327 nm (ɛ = 20 500, 15 200, 8100). ^1^H NMR (DMSO-*d*~6~): δ = 2.10--2.17, 2.38--2.50 \[2m, 2 H, H-C(2′)\]; 3.14, 3.19 (2s, 6 H, Me~2~N); 3.50--3.52 \[m, 2 H, H-C(5′)\]; 3.77--3.80 \[m, 1 H, H-C(4′)\]; 4.31--4.33 \[m, 1 H, H-C(3′)\]; 4.94 \['t', 1 H, *J* = 5.2 Hz, OH-C(5′)\]; 5.28 \[d, 1 H, *J* = 3.4 Hz, OH-C(3′)\]; 6.48 \[d, 1 H, *J* = 6.1 Hz, H-C(1′)\]; 7.46 \[s, 1 H, H-C(6)\]; 8.84 (s, 1 H, N=CH); 9.48 (d, 1 H, *J* = 9.9 Hz, NH); 10.47 (d, *J* = 9.9 Hz, 1 H, COH). Anal. calc. for C~15~H~19~ClN~6~O~4~(382.80): C, 47.06; H, 5.00; N, 21.95; found: C, 47.15; H, 5.06; N, 21.81.

*5-Bromo-7-(2-deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****7c***). Compound **7c** was prepared from 5-bromo-7-(2-deoxy-β-[d]{.smallcaps}-*erythro*-pentofuranosyl)-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-2,4-diamine (**2c**) ([@b25]) (480 mg, 1.39 mmol) and *N,N*-dimethylformamide dimethylacetal (3.0 ml, 22.4 mmol) as described for **7a**. FC (silica gel, column 4 × 10 cm, elution with CH~2~Cl~2~/MeOH, 95:5) resulted in a colorless foam (450 mg, 76%). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.33. UV (MeOH): 238, 274, 328 nm (ɛ = 20 800, 15 600, 9400). ^1^H NMR (DMSO-*d*~6~): δ = 2.13--2.17, 2.39--2.45 \[2m, 2 H, H-C(2′)\]; 3.17, 3.19 (2s, 6 H, Me~2~N); 3.35--3.54 \[m, 2 H, H-C(5′)\]; 3.78--3.79 \[m, 1 H, H-C(4′)\]; 4.30--4.32 \[m, 1 H, H-C(3′)\]; 4.93 \['t', 1 H, *J* = 5.4 Hz, OH-C(5′)\]; 5.27 \[d, 1 H, *J* = 3.7 Hz, OH-C(3′)\]; 6.47 \[dd, 1 H, *J* = 5.9, 8.3 Hz, H-C(1′)\]; 7.51 \[s, 1 H, H-C(6)\]; 8.84 (s, 1 H, N = CH); 9.48 (d, 1 H, *J* = 10.1 Hz, NH); 10.47 (d, *J* = 10.1 Hz, 1 H, COH). Anal. calc. for C~15~H~19~BrN~6~O~4~ (427.25): C, 42.17; H, 4.48; N, 19.67; found: C, 42.33; H, 4.40; N, 19.43.

*7-(2-Deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-4-\[(dimethylamino)methylidene\]amino-2-formylamino-5-iodo-7H-pyrrolo\[2,3-d\]pyrimidine (****7d***). Compound **7d** was prepared from 7-(2-deoxy-β-[d]{.smallcaps}-*erythro*-pentofuranosyl)-5-iodo-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-2,4-diamine (**2d**) ([@b25]) (200 mg, 0.51 mmol) and *N,N*-dimethylformamide dimethylacetal (1.0 ml, 7.5 mmol) as described for **7a**. FC (silica gel, column 4 × 10 cm, elution with CH~2~Cl~2~/MeOH, 95:5) resulted in a colorless foam (189 mg, 78%). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.33. UV (MeOH): λ~max~ = 256, 330 nm (ɛ = 22 500, 12 700). ^1^H NMR (DMSO-*d*~6~): δ = 2.11--2.16, 2.40--2.45 \[2m, 2 H, H-C(2′)\]; 3.19, 3.22 (2s, 6 H, Me~2~N); 3.50--3.52 \[m, 2 H, H-C(5′)\]; 3.77--3.79 \[m, 1 H, H-C(4′)\]; 4.30--4.32 \[m, 1 H, H-C(3′)\]; 4.94 \['t', 1 H, *J* = 5.3 Hz, OH-C(5′)\]; 5.28 \[d, 1 H, *J* = 3.6 Hz, OH-C(3′)\]; 6.44 \[d, 1 H, *J* = 6.2 Hz, H-C(1′)\]; 7.53 \[s, 1 H, H-C(6)\]; 8.85 (s, 1 H, N = CH), 9.47 (d, 1 H, *J* = 10.2 Hz, NH), 10.44 (d, *J* = 10.2 Hz, 1 H, COH). Anal. calc. for C~15~H~19~IN~6~O~4~ (474.25): C, 37.99; H, 4.04; N, 17.72; found: C, 38.00; H, 4.10; N, 17.40.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****8a***). Compound **7a** (300 mg, 0.86 mmol) was co-evaporated with anhydrous pyridine (three times) and then dissolved in pyridine (2.0 ml). To this solution 4,4′-dimethoxytriphenylmethyl chloride (DMT-Cl) (348 mg, 1.03 mmol) was added and the mixture was stirred at room temperature for 3 h. The reaction was quenched by the addition of MeOH and the mixture was evaporated to dryness. It was dissolved in CH~2~Cl~2~ (3.0 ml) and subjected to FC (column 4 × 9 cm, elution with CH~2~Cl~2~/MeOH, 98:2) to give a colorless foam (460 mg, 82%). TLC (silica gel, CH~2~Cl~2~/MeOH, 98:2): *R*~f~ 0.23. UV (MeOH): λ~max~ = 236, 323 (ɛ = 35 600, 17 500). ^1^H NMR (DMSO-*d*~6~): δ = 2.24--2.28, 2.50--2.57 \[2m, 2 H, H-C(2′)\]; 3.10--3.17 \[m, 8 H, Me~2~N, H-C(5′)\]; 3.71 (s, 6 H, 2MeO); 3.89--3.91 \[m, 1 H, H-C(4′)\]; 4.34--4.36 \[m, 1 H, H-C(3′)\]; 5.36 \[d, 1 H, *J* = 4.0 Hz, OH-C(3′)\]; 6.45--6.52 \[m, 2 H, H-C(1′); H-C(5)\]; 6.79--6.84 (m, 4 H, arom. H); 7.16--7.37 \[m, 10 H, 9 arom. H, H-C(6)\]; 8.82 (s, 1 H, N = CH); 9.47 (d, 1 H, *J* = 10.2 Hz, NH); 10.40 (d, *J* = 10.2 Hz, 1 H, COH). Anal. calc. for C~36~H~38~N~6~O~6~ (650.72): C, 66.45; H, 5.89; N, 12.91; found: C, 66.36; H, 6.00; N, 12.75.

*5-Chloro-7-\[2-deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****8b***). Compound **8b** was prepared from **7b** (500 mg, 1.31 mmol) and DMT-Cl (594 mg, 1.75 mmol) as described for **8a**. FC (column 4 × 9 cm, elution with CH~2~Cl~2~/MeOH, 98:2) produced a colorless foam (781 mg, 87%). TLC (silica gel, CH~2~Cl~2~/MeOH, 95:5): *R*~f~ 0.26. UV (MeOH): λ~max~ = 237, 248, 327 nm (ɛ = 34 800, 32 200, 18 000). ^1^H NMR (DMSO-*d*~6~): δ = 2.21--2.24, 2.50--2.58 \[2m, 2 H, H-C(2′)\]; 3.05--3.19 \[m, 8 H, Me~2~N, H-C(5′)\]; 3.72 (s, 6 H, 2MeO); 3.89--3.91 \[m, 1 H, H-C(4′)\]; 4.33--4.35 \[m, 1 H, H-C(3′)\]; 5.32 \[d, 1 H, *J* = 4.1 Hz, OH-C(3′)\]; 6.48 \[d, 1 H, *J* = 6.6 Hz, H-C(1′)\]; 6.81--6.86 (m, 4 H, arom. H); 7.21--7.37 \[m, 10 H, 9 arom. H, H-C(6)\]; 8.84 (s, 1 H, N = CH); 9.48 (d, 1 H, *J* = 10.0 Hz, NH); 10.50 (d, *J* = 10.0 Hz, 1 H, COH). Anal. calc. for C~36~H~37~ClN~6~O~6~ (685.17): C, 63.11; H, 5.44; N, 12.27; found: C, 63.20; H, 5.30; N, 12.15.

*5-Bromo-7-\[2-deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine (****8c***). Compound **8c** was prepared from **7c** (369 mg, 0.86 mmol) and DMT-Cl (350 mg, 1.03 mmol) as described for **8a**. FC (column 4 × 9 cm, elution with CH~2~Cl~2~/MeOH, 98:2) produced a colorless foam (533 mg, 85%). TLC (silica gel, CH~2~Cl~2~/MeOH, 95:5): *R*~f~ 0.26. UV (MeOH): λ~max~ = 237, 250, 329 (ɛ =35 400, 32 400, 18 400). ^1^H NMR (DMSO-*d*~6~): δ = 2.20--2.26, 2.49--2.57 \[2m, 2 H, H-C(2′)\]; 3.06--3.19 \[m, 8 H, Me~2~N, H-C(5′)\]; 3.72 (m, 6 H, 2MeO); 3.90--3.92 \[m, 1 H, H-C(4′)\]; 4.34--4.36 \[m, 1 H, H-C(3′)\]; 5.32 \[d, 1 H, *J* = 4.1 Hz, OH-C(3′)\]; 6.48 \['t', 1 H, *J* = 7.0 Hz, H-C(1′)\]; 6.81--6.86 (m, 4 H, arom. H); 7.20--7.37 \[m, 10 H, 9 arom. H, H-C(6)\]; 8.84 (s, 1 H, N=CH); 9.48 (d, 1 H, *J* = 10.1 Hz, NH); 10.49 (d, *J* = 10.1 Hz, 1 H, COH). Anal. calc. for C~36~H~37~BrN~6~O~6~ (729.62): C, 59.26; H, 5.11; N, 11.52; found: C, 59.23; H, 5.02; N, 11.55.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-5-iodo-7H-pyrrolo\[2,3-d\]pyrimidine (****8d***). Compound **8d** was prepared from **7d** (194 mg, 0.41 mmol) and DMT-Cl (139 mg, 0.41 mmol) as described for **8a**. FC (column 4 × 9 cm, elution with CH~2~Cl~2~/MeOH, 98:2) produced a colorless foam (274 mg, 86%). TLC (silica gel, CH~2~Cl~2~/MeOH, 95:5): *R*~f~ 0.26. UV (MeOH): λ~max~ = 236, 254, 332 (33 400, 30 500, 16 800). ^1^H NMR (DMSO-*d*~6~): δ = 2.20--2.24, 2.50--2.60 \[2m, 2 H, H-C(2′)\]; 3.05--3.21 \[m, 8 H, Me~2~N, H-C(5′)\]; 3.72 (s, 6 H, 2 MeO); 3.89--3.91 \[m, 1 H, H-C(4′)\]; 4.34--4.36 \[m, 1 H, H-C(3′)\]; 5.35 \[d, 1 H, *J* = 3.9 Hz, OH-C(3′)\]; 6.45 \['t', 1 H, *J* = 6.6 Hz, H-C(1′)\]; 6.81--6.86 (m, 4 H, arom. H); 7.22--7.40 \[m, 10 H, 9 arom. H, H-C(6)\]; 8.85 (s, 1 H, N=CH); 9.46 (d, 1 H, *J* = 10.1 Hz, NH); 10.45 (d, *J* = 10.2 Hz, 1 H, COH). Anal. calc. for C~36~H~37~IN~6~O~6~ (776.62): C, 55.68; H, 4.80; N, 10.82; found: C, 55.95; H, 4.98; N, 10.41.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine 3′-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (****5a***). Compound **8a** (200 mg, 0.31 mmol) dissolved in anhydrous CH~2~Cl~2~ (3.0 ml) under Ar was reacted with 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (100 μl, 0.42 mmol) in the presence of (*^i^*Pr)~2~NEt (100 μl) at room temperature. After 30 min, the reaction mixture was diluted with CH~2~Cl~2~ and the solution was washed with a 5% aqueous NaHCO~3~ solution, followed by brine. The organic solution was dried over anhydrous Na~2~SO~4~, filtrated and concentrated. The residue was submitted to FC (column 3 × 9 cm, CH~2~Cl~2~/acetone, 95:5) yielding a colorless foam (206 mg, 78%). TLC (silica gel, CH~2~Cl~2~/acetone, 9:1): *R*~f~ 0.2, 0.26. ^31^P NMR (CDCl~3~): 149.6, 149.8.

*5-Chloro-7-\[2-deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine 3′-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (****5b***). Compound **8b** (400 mg, 0.58 mmol) was treated with (*^i^*Pr)~2~NEt (157 μl) and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (157 μl, 0.70 mmol) as described for **5a**. FC (column 3 × 9 cm, CH~2~Cl~2~/acetone, 95:5) resulted in a colorless foam (363 mg, 71%). TLC (CH~2~Cl~2~/acetone, 9:1): *R*~f~ 0.23, 0.30. ^31^P NMR (CDCl~3~): 149.7, 149.9.

*5-Bromo-7-\[2-deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-7H-pyrrolo\[2,3-d\]pyrimidine 3′-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (****5c***). Compound **8c** (400 mg, 0.55 mmol) was treated with (*^i^*Pr)~2~NEt (157 μl) and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (157 μl, 0.70 mmol) as described for **5a**. FC (column 3 × 9 cm, CH~2~Cl~2~/acetone, 95:5) resulted in a colorless foam (384 mg, 75%). TLC (CH~2~Cl~2~/acetone, 9:1): *R*~f~ 0.23, 0.30. ^31^P NMR (CDCl~3~): 149.8, 150.0.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-formylamino-5-iodo-7H-pyrrolo\[2,3-d\]pyrimidine 3′-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (****5d***). Compound **8d** (250 mg, 0.32 mmol) was treated with (*^i^*Pr)~2~NEt (80 μl) and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (100 μl, 0.42 mmol) as described for **5a**. FC (column 3 × 9 cm, CH~2~Cl~2~/acetone, 95:5) resulted in a colorless foam (249 mg, 80%). TLC (CH~2~Cl~2~/acetone, 9:1): *R*~f~ 0.23, 0.30. ^31^P NMR (CDCl~3~): 149.9, 150.1.

*7H-Pyrrolo\[2,3-d\]pyrimidin-2,4-diamine (****10***). A suspension of 4-chloro-7*H*-pyrrolo\[2,3-*d*\]pyrimidin-2-amine ([@b24]) (**9**: 4.0 g, 23.73 mmol) in dioxane (60 ml) and 25% aq. NH~3~ (160 ml) was introduced into an autoclave and stirred at 100°C for 24 h. The clear solution was evaporated to remove ammonia (→ half the volume). The solution was applied to a *Serdolit* AD-4 column (4 × 20 cm, resin 0.1--0.2 mm; *Serva*, Germany), the column was washed with H~2~O (200 ml) and the product was eluted with H~2~O/*^i^*PrOH (5:1, 500 ml). The product-containing fractions were combined and the solvent was evaporated to give compound **10** as yellowish foam (3.22 g, 91%). TLC (CH~2~Cl~2~/MeOH, 5:1): *R*~f~ 0.25. ^1^H NMR (DMSO-*d*~6~): δ = 6.51 \[d, 1 H, *J* = 3.4 Hz, H-C(5)\]; 6.70 (br. s, 2 H, NH~2~); 6.81 \[d, 1 H, *J* = 3.4 Hz, H-C(6)\]; 7.85 (br. s, 2 H, NH~2~); 11.43 (s, 1 H, NH). ^13^C-NMR (DMSO-*d*~6~): δ = 154.3, 153.8, 149.6, 119.4, 100.7, 95.0. Anal. calc. for C~6~H~7~N~5~ (149.15): C, 48.32; H, 4.73; N, 46.95; found: C, 48.30; H, 4.80; N, 46.80.

*2-Fluoro-7H-pyrrolo\[2,3-d\]pyrimidin-4-amine (****11***). Into a stirred solution of **10** (2.0 g, 13.41 mmol) in HF/pyridine (15 ml) (a tefelon flask), which was cooled to −50°C, *^t^*BuNO~2~ (1.78 ml) was dropwise in 30 min. The reaction mixture was stirred at −60 to −50°C for 7 h, poured on a stirred ice-cooled CaCO~3~ powder (30 g) and allowed to stay overnight. The product was extracted with MeOH (100 ml) and was further purified by FC (column 4 × 9 cm, elution with CH~2~Cl~2~/MeOH, 98:2 → 9:1) to give compound **10** as a yellowish solid (612 mg, 30%) \[small amounts of by-products were separated (Supplementary Data)\]. TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.43. ^1^H NMR (DMSO-*d*~6~): δ = 6.53 \[d, 1 H, *J* = 2.4 Hz, H-C(5)\]; 7.01 \[d, 1 H, *J* = 2.4 Hz, H-C(6)\]; 7.41 (br. s, 2 H, NH~2~); 11.56 (s, 1 H, NH). ^19^F NMR (DMSO-*d*~6~): −55.1. Anal. calc. for C~6~H~5~FN~4~ (152.13): C, 47.37; H, 3.31; N, 36.83; found: C, 47.10; H, 3.43; N, 36.66.

*7-\[2-Deoxy-3,5-di-O-(p-toluoyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-2-fluoro-7H-pyrrolo\[2,3-d\]pyrimidin-4-amine* (***13***). Into a suspension of powdered KOH (494 mg, 85%, 7.4 mmol) and TDA-1 (0.2 ml, 0.63 mmol) in MeCN (30 ml), compound **11** (456 mg, 3.00 mmol) was added. After the mixture was stirred for 5 min, sugar halide **12** ([@b26]) (1.38 g, 3.55 mmol) was added during 5 min and the stirring was continued for 10 min. Insoluble material was filtered off, the precipitate was washed with MeCN and the filtrate was evaporated to dryness. The residue was applied to FC (silica gel column 4 × 12 cm, elution with CH~2~Cl~2~/MeOH, 100:0 → 99:1). The product-containing fractions were combined and evaporated to give a colorless foam (1.12 g, 74%). TLC (silica gel, CH~2~Cl~2~/MeOH, 98:2): *R*~f~ 0.23. ^1^H NMR (CDCl~3~): δ = 2.42, 2.44 (2s, 6 H, 2Me); 2.72--2.77 \[m, 2 H, H-C(2′)\]; 4.57--4.71 \[m, 3H, H-C(4′), H-C(5′)\]; 5.50 (br. s, 2 H, NH~2~); 5.69--5.71 \[m, 1 H, H-C(3′)\]; 6.36 \[d, 1 H, J = 3.7 Hz, H-C(5)\]; 6.70 \['t', 1 H, *J* = 7.0 Hz, H-C(1′)\]; 7.09 \[d, 1 H, J = 3.7 Hz, H-C(6)\]; 7.23--7.30, 7.93--7.99 (2m, 8 H, 2C~6~H~4~). ^19^F NMR (DMSO-*d*~6~): −97.4. Anal. calc. for C~27~H~25~FN~4~O~5~ (504.51): C, 64.28; H, 4.99; N, 11.11; found: C, 64.10; H, 4.83; N, 11.10.

*7-(2-Deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-2-fluoro-7H-pyrrolo\[2,3-d\]pyrimidin-4-amine (****3***). Compound **13** (0.9 g, 1.78 mmol) was dissolved in NH~3~/MeOH (methanol saturated with ammonia at 0°C, 50 ml) and stirred at room temperature for 16 h. After removal of the solvent, the residue was dissolved in MeOH and adsorbed on a small amount (4.0 g) of silica gel. This material was loaded on the top of a silica gel column (4 × 9 cm), and the product was eluted stepwise with CH~2~Cl~2~/MeOH (98:2, 300 ml) and CH~2~Cl~2~/MeOH (9:1, 600 ml). The product-containing fractions were combined and the solvent was evaporated to give a yellowish solid (405 mg, 85%). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.27. UV (MeOH): λ~max~ = 221, 269 (ɛ = 15 400, 10 800). ^1^H NMR (DMSO-*d*~6~): δ = 2.11--2.18, 2.39--2.50 \[2m, 2 H, H-C(2′)\]; 3.48--3.59 \[m, 1 H, H-C(5′)\]; 3.79--3.81 \[m, 1 H, H-C(4′)\]; 4.31--4.33 \[m, 1 H, H-C(3′)\]; 4.94 \['t', 1 H, *J* = 5.4 Hz, OH-C(5′)\]; 5.28 \[d, 1 H, *J* = 4.0 Hz, OH-C(3′)\]; 6.33 \['t', 1 H, *J* = 7.0 Hz, H-C(5′)\]; 6.60 \[d, 1 H, *J* = 3.5 Hz, H-C(5)\]; 7.30 \[d, 1 H, *J* = 3.5 Hz, H-C(6)\]; 7.55 (br. s, 2 H, NH~2~). ^19^F NMR (DMSO-*d*~6~): −54.2. Anal. calc. for C~11~H~13~FN~4~O~3~ (268.24): C, 49.25; H, 4.88; N, 20.89; found: C, 49.33; H, 4.89; N, 21.04.

*7-(2-Deoxy-β-[d]{.smallcaps}-erythro-pentofuranosyl)-4-\[(dimethylamino)methylidene\]amino-2-fluoro-7H-pyrrolo\[2,3-d\]pyrimidine (****14***). A solution of compound **3** (268 mg, 1.0 mmol) in MeOH (10 ml) was stirred with *N,N*-dimethylformamide dimethylacetal (2.0 ml, 14.9 mmol) for 18 h at room temperature. After evaporation, the residue was applied to FC (silica gel, column 4 × 10 cm, elution with CH~2~Cl~2~/MeOH, 95:5) yielding a yellowish foam (272 mg, 84 %). TLC (silica gel, CH~2~Cl~2~/MeOH, 9:1): *R*~f~ 0.44. UV (MeOH): λ~max~ = 223, 261, 320 nm (ɛ = 14 400, 11 000, 20 100). ^1^H NMR (DMSO-*d*~6~): δ = 2.15--2.22, 2.43--2.50 \[2m, 2 H, H-C(2′)\]; 3.13, 3.20 (2s, 6 H, Me~2~N); 3.49--3.58 \[m, 2 H, H-C(5′)\]; 3.79--3.81 \[m, 1 H, H-C(4′)\]; 4.33--4.34 \[m, 1 H, H-C(3′)\]; 4.96 \['t', 1 H, *J* = 5.2 Hz, OH-C(5′)\]; 5.31 \[d, 1 H, *J* = 4.0 Hz, OH-C(3′)\]; 6.41 \['t', 1 H, *J* = 7.0 Hz, H-C(1′)\], 6.55 \[d, 1 H, *J* = 3.5 Hz, H-C(5)\]; 7.47 \[d, 1 H, *J* = 3.5 Hz, H-C(6)\]; 8.76 (s, 1 H, N = CH). ^19^F NMR (DMSO-*d*~6~): −53.6. Anal. calc. for C~14~H~18~FN~5~O~3~ (323.32): C, 52.01; H, 5.61; N, 21.66; found: C, 51.62; H, 5.57; N, 21.63.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-fluoro-7H-pyrrolo\[2,3-d\]pyrimidine (****15***). Compound **15** (323 mg, 1.0 mmol) was co-evaporated with anhydrous pyridine (three times) and then dissolved in pyridine (4.0 ml). To this solution DMT-Cl (405 mg, 1.2 mmol) was added and the mixture was stirred at room temperature for 3 h. The reaction was quenched by the addition of MeOH and the mixture was evaporated to dryness. It was dissolved in CH~2~Cl~2~ (3.0 ml) and subjected to FC (column 4 × 12 cm, elution with CH~2~Cl~2~/MeOH, 98:2) to give a colorless foam (438 mg, 70%). TLC (silica gel, CH~2~Cl~2~/MeOH, 95:5): *R*~f~ 0.40. UV (MeOH): λ~max~ = 235, 263, 326 (ɛ = 34 900, 14 400, 23 000). ^1^H NMR (DMSO-*d*~6~): δ = 2.23--2.28 \[m, 1 H, H-C(2′)\]; 2.50--2.58 \[m, 1 H, H-C(2′)\]; 3.12--3.20 \[m, 8 H, Me~2~N, H-C(5′)\]; 3.71 (s, 6 H, 2OMe); 3.91--3.93 \[m, 1 H, H-C(4′)\]; 4.36--4.37 \[m, 1 H, H-C(3′)\]; 5.38 \[d, 1 H, *J* = 4.4 Hz, OH-C(3′)\]; 6.43 \['t', 1 H, *J* = 6.4 Hz, H-C(1′)\]; 6.53 \[d, 1 H, *J* = 3.5 Hz, H-C(5)\]; 6.79--6.84 (m, 4 H, arom H); 7.20--7.48 \[m, 10 H, arom H, H-C(6)\]; 8.78 (s, 1 H, N = CH). ^19^F NMR (DMSO-*d*~6~): −53.3. Anal. calc. for C~35~H~36~FN~5~O~5~ (625.69): C, 67.19; H, 5.80; N, 11.19; found: C, 66.81; H, 5.74; N, 11.01.

*7-\[2-Deoxy-5-O-(4,4′-dimethoxytriphenylmethyl)-β-[d]{.smallcaps}-erythro-pentofuranosyl\]-4-\[(dimethylamino)methylidene\]amino-2-fluoro-7H-pyrrolo\[2,3-d\]pyrimidine 3′-(2-cyanoethyl)-N,N-diisopropylphosphoramidite (****6***). Compound **15** (313 mg, 0.50 mmol) was treated with (*^i^*Pr)~2~NEt (157 μl) and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite (134 μl, 0.60 mmol) as described for **5a**. FC (column 3 × 9 cm, CH~2~Cl~2~/acetone, 95:5) resulted in a colorless foam (289 mg, 70%). TLC (CH~2~Cl~2~/acetone, 95:5): *R*~f~ 0.32, 0.41. ^31^P NMR (CDCl~3~): 149.7, 149.9.

RESULTS AND DISCUSSION
======================

Monomers
--------

The phosphoramidites of 2′-deoxytubercidin (**1a**) and its 7-iodo-derivative (**1d**) as well as that of compound **4** have already been described ([@b19]--[@b21]). Compound **2a** was prepared according to ([@b24]) and the synthesis of its 7-halogenated derivatives **2b**--**d** refers to ([@b25]). As the *N,N*-dialkylaminomethylidene protecting groups had already been successfully employed in the case of related 2,6-diaminopurine nucleosides ([@b13],[@b16],[@b27]), now a similar strategy was chosen for **2a**--**d**. Nucleosides **2a**--**d** were treated with *N,N*-dimethylformamide dimethylacetal in methanol yielding the bis-amidine \[**7a**--**d**\] ([Scheme 2](#sch2){ref-type="fig"}). After work-up, the *N,N*-dimethylaminomethylidene residue was partially hydrolyzed during silica gel FC resulting in a mixture of compounds \[**7a**--**d**\] and **7a**--**d**. This was established on the basis of TLC and NMR data. As a typical example, the analytical data of compound \[**7c**\] is given in Supplementary Data. A complete and selective conversion of the amidine residue at position-2 to a formyl group was accomplished by the addition of traces of water to the methanolic solution of \[**7a**--**d**\] while stirring at 30--40°C for 48 h. This resulted in compounds **7a**--**d**. As problems regarding the stability of amidine protection were reported for 2-amino-7-deaza-2′-deoxy-7-propynyladenosine ([@b28]), the half-lives of deprotection were measured for compounds **7a**--**d** UV-spectrophotometrically (25% aq. NH~3~ at 40°C). The apparent values for the complete deprotection are 53 min for **7a**, 35 min for **7b**, 36 min for **7c** and 50 min for **7d**. Subsequently, the 5′-hydroxyl groups were protected with the 4,4′-dimethoxytrityl (DMT) residues to give nucleosides **8a**--**d**. Phosphitylation of the latter performed in anhydrous CH~2~Cl~2~ in the presence of ^i^Pr~2~EtN and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite, furnished the phosphoramidites **5a**--**d**.

Next, the syntheses of the 2-fluoro-7-deazaadenine nucleoside **3** and its phosphoramidite were performed ([Scheme 3](#sch3){ref-type="fig"}). As the diazotization/fluorination reaction required strong acid conditions (HF/pyridine) ([@b29]), it resulted in the decomposition of the 2,6-diamino nucleoside **2a**. Thus, the nucleobase **10** was used instead of the nucleoside. As a precursor the 2-amino-6-chloro-7-deazapurine (**9**) ([@b24]) was employed, which was converted to the diamino compound **10** in aqeous ammonia (autoclave, 100°C). The diazotization/fluorination reaction was performed under the same conditions as done for **2a** by dropwise addition of *^t^*BuNO~2~ affording the 2-fluoro base **11**. The low yield of **11** (30%) is caused by the partial fluorination at the 6-position giving 2,6-difluoro-7-deazapurine, in which the 6-fluoro group was displaced by nucleophiles such as MeOH (→2-fluoro-6-methoxy-7-deazapurine) (Supplementary Data). Nucleobase-anion glycosylation of **11** with 2-deoxy-3,5-di-*O*-(*p*-toluoyl)-α-[d]{.smallcaps}-*erythro*-pentofuranosyl chloride (**12**) yielded the toluoyl-protected β-[d]{.smallcaps}-nucleoside **13** (74% yield; [Scheme 3](#sch3){ref-type="fig"}). Compound **13** was converted to the 2-fluoro nucleoside **3** in methanolic ammonia at room temperature. The 2-amino group of **3** was protected by the *N,N*-dimethylaminomethylidene residue to give **14**, which shows a half-life value of 19 min (25% aqeous ammonia, room temperature). Subsequently, compound **14** was converted into the 5′-*O*-DMT-derivative **15** under standard conditions. Phosphitylation of **15** was performed in anhydrous CH~2~Cl~2~ in the presence of *^i^*Pr~2~EtN and 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite, furnishing the phosphoramidite **6**. The reactions performed with the 2-fluoro nucleosides were carried out at room temperature in order to avoid the displacement of the 2-fluoro substituent. As 2′-deoxy-2-fluorotubercidin is a convertible nucleoside, it can be used to generate DNA containing modified nucleosides with various substituents at the 2-position by using elevated temperature and/or different deprotection conditions leading to fluorine displacement.

All compounds were characterized by ^1^H-, ^13^C-, ^31^P- or ^19^F-NMR spectra as well as by elemental analysis. ^13^C-NMR shift assignment was made according to gated-decoupled spectra and to those of the free nucleosides ([Table 1](#tbl1){ref-type="table"}) ([@b24],[@b25]). Compared with the non-functionalized compounds **7a** or **8a**, the C-7 signal is shifted upfield ∼12 p.p.m. upon bromination (**7c** and **8c**) and ∼50 p.p.m. upon iodination (**7d** and **8d**), but locates downfield upon chlorination (∼3 p.p.m. for **7b** and **8b**). In comparison to the parent compound **1a** ([@b24]), the 2-fluoro substituent of nucleoside **3** causes a downfield shift (∼9 p.p.m.) at C-2 in the ^13^C-NMR spectrum with a ^1^J~C,F~ coupling constant of 200 Hz, two ^3^J~C,F~ couplings of 15--20 p.p.m. for C-4 or C-6 and ∼4 p.p.m. for C-5.

Oligonucleotides
----------------

### Base-pairing properties of oligonucleotides containing the modified nucleosides **1a**, **1d**, **2a--d**, **3** and **4**

For all hybridization experiments studying the influence of the base-modified nucleosides on the duplex stability, the duplex 5′-d(TAGGTCAATACT) (**16**) 3′-d(ATCCAGTTATGA) (**17**) was used as reference. The modified duplexes contain single or multiple incorporations of the base-modified compounds at various positions. The base pairing of the oligonucleotides with the four canonical nucleosides opposite to the modification sites was investigated. For compounds **1a**, **1d**, **2a**, **2b**, **3** and **4** the mismatch discrimination was studied at various pH values.

### Duplex stability of oligonucleotides with anti-parallel strand (aps) orientation

The base pair stability of 2′-deoxytubercidin (**1a**) or its 7-halogenated derivatives in oligonucleotide duplexes has already been studied ([@b11],[@b15],[@b20]). Very little is known about the influence of the 7-halogen substituents of the 2-amino-2′-deoxytubercidin derivatives **2b**--**d** on the base pairing properties ([@b28]). Also the effect of small substituents introduced at the 2-position of pyrrolo\[2,3-*d*\]pyrimidine on the base pair stability is unknown and is now studied with the 2-fluorinated 2′-deoxytubercidin **3**. Moreover, the effect of the amino group in the 2- or 6-position of a 7-deazapurine is investigated by comparing the duplex stability and mismatch discrimination of 2-amino-7-deazapurine-2′-deoxyribonucleoside (**4**) with **1a**. Hybridization experiments were performed with oligonucleotides containing **2a**--**d** as well as **3** and **4**. For comparison, oligonucleotides incorporating **1a** and its 7-iodo derivative **1d** at the same position as **2a**--**d** were investigated. [Table 2](#tbl2){ref-type="table"} summarizes the *T*~m~ values of oligonucleotides containing **1a**, **1d**, **2**--**4** with one to six modifications.

In a first series of experiments, the influence of 7-substituents on the oligonucleotide duplexes stability was studied replacing dA-residues in the duplex **16·17** (47°C) by compounds **1a**, **1d** and **2a**--**d**. According to [Table 2](#tbl2){ref-type="table"} the replacement of one or two dA-residues by 2′-deoxytubercidin (**1a**: *T*~m~ = 46°C for duplex **18**·**17** and **16**·**19**) has very little influence on the duplex stability. Similar results were observed for the non-functionalized 2-amino-2′-deoxytubercidin (**2a**: 47°C for duplex **22**·**17** and **16**·**23**). This shows that the 2-amino group present in the non-halogenated **2a** contributes very little to the stability of **2a**-dT base pairs (motif iia, [Figure 1](#fig1){ref-type="fig"}). However, the 7-halogen substituents in **2a** stabilize the duplex significantly (see *T*~m~ values of duplexes incorporating **2b**--**d** in [Table 2](#tbl2){ref-type="table"}). The stabilizing effect of 7-halogenated 7-deazapurin-2,6-diamine nucleosides (**2b**--**d**: Δ*T*~m~ = 2.0--3.0°C per modification) is stronger than that of the 7-substituted 2′-deoxytubercidin (**1d**: Δ*T*~m~ = 1.0°C). These results show that the additional 2-amino group of compound **2a** being not functionalized at 7-position does not strengthen the base pair (47°C) in comparison to 2′-deoxytubercidin (46°C), whereas in the case of 7-halogenated nucleosides the 2-amino group of **2b**--**d** makes a contribution to the base pair stability (**2d**: 50°C or 53°C for duplexes **33·17** and **16·34** versus **1d**: 48°C or 50°C for duplexes **20·17** or **16·21**). This might result from the better proton donor properties of the 2-amino group of the 7-halogenated nucleosides **2b**--**d**. A comparison of the p*K*~a~ values of **2a** (5.71) with 7-halogen derivatives (**2b**: 4.86; **2c**: 4.85; **2d**: 4.75) shows that 7-halogen substituents reduce the basicity of the 7-deazapurin-2,6-diamine. At the same time, the 2-amino group can become a better proton donor, thereby strengthening the **2b**--**d**-dT base pair (motif iib--d, [Figure 1](#fig1){ref-type="fig"}).

In order to prove the effect of multiple incorporations of the halogenated nucleosides, we determined *T*~m~ values in dependence of an increasing number of modified bases. The oligonucleotides containing **2b** or **2c** in a consecutive manner or in distant position were synthesized. The total number of incorporations was increased in duplexes from 1 to 6. It was found that the *T*~m~ values increased steadily by an increasing number of modified residues ([Table 2](#tbl2){ref-type="table"}). The linear relationship of *T*~m~ values with the modification numbers of **2b** and **2c** is shown in [Figure 2A](#fig2){ref-type="fig"} (**2b**) and B (**2c**).

In the second series of hybridization experiments, the stabilizing effect of the 2-amino versus the 6-amino group was evaluated. For this, oligonucleotides containing the 2-amino-7-deazapurine nucleoside **4** were synthesized ([Table 2](#tbl2){ref-type="table"}). It was observed that the duplex **16·36** (47°C) incorporating **4** shows the same stability as that containing **1a** having an amino function in the 6-position (46°C for duplex **18·17**). This indicates that the amino group in the 2- (**4**) or 6-position (**1a**) of 7-deazapurines plays a similar role on the base pair stability when pairing with dT. Obviously, a bidentate base pair is formed between **4** and dT (motif iv, [Figure 1](#fig1){ref-type="fig"}).

The effect of 2-halogen substituent on the duplex stability was also investigated. For this purpose the 7-deaza-2-fluoro-2′-deoxyadenosine (**3**) was incorporated at exactly the same positions as the other modified derivatives. According to [Table 2](#tbl2){ref-type="table"}, compound **3** decreases the duplex stability by 3°C per modification (duplex **16**·**35**). Owing to its negative effect, multiple incorporations of **3** were not undertaken. The destabilization of the nucleoside **3** results from the presence of the 2-fluoro group. Its electron-withdrawing property decreases the proton acceptor ability of nitrogen-1 causing weaker hydrogen bonding within the base pair (motif iii, [Figure 1](#fig1){ref-type="fig"}), which is underlined by the p*K*~a~-value (\<1.5) of **3** (Supplementary Data). In addition, the 2-fluoro substituent induces steric strain with the 2-oxo group of dT.

### Stability of duplexes with parallel chain orientation

It is already reported that 7-halogenated 2′-deoxytubercidin derivatives, such as **1d**, show a stabilizing effect on parallel-stranded (*ps*) DNA ([@b30]). Here, the base pairing of the 2-amino derivatives **2a**--**d** in *ps* DNA was investigated. In order to induce parallel chain orientation two 'iG~d~--dC' and two '^Me^iC~d~--dG' base pairs were introduced instead of the dG--dC pairs. The duplexes **37·17** and **16·38** with modifications in different positions served as standards. According to [Table 3](#tbl3){ref-type="table"} the substitution of dA residues by the non-halogenated nucleoside **2a** decreases the stability of the *ps* duplexes by 1°C per modification (duplex **37**·**23**) ([Table 3](#tbl3){ref-type="table"}), whereas the incorporation of 7-halogenated nucleosides **2b**--**d** into the *ps* DNA led to an increase of the *ps* duplex stability by 1--2.0°C per modification depending on the sequences (see *T*~m~ values of duplexes incorporating **2b**--**d** in [Table 3](#tbl3){ref-type="table"}). These results show that the 7-halogen substituents introduced in 2-amino-7-deazaadenine nucleosides are well accommodated in the grooves of *ps*-DNA and stabilize *ps* duplexes structure. Similar to dA--dT base pair motif v, the motifs via-d are suggested for the **2a**--**d**-dT pairs in *ps* DNA ([Figure 3](#fig3){ref-type="fig"}).

### Mismatch discrimination

It is generally accepted that transition mutations *in vivo* proceed via the formation of base mispairs during DNA replication. Several mechanisms have been postulated to explain base mispair formation including rare tautomeric forms ([@b1],[@b31]), ionized bases ([@b32]) and wobble base pairs ([@b33],[@b34]). Different motifs have been proposed for hydrogen bonding between cytosine and adenine, involving major ([@b1],[@b35]) or minor tautomer forms of the bases ([@b36]). Most of the models lack direct experimental evidence. Hunter *et al.* ([@b37]) have reported the crystal structure of a dA--dC base pair, which shows that the protonated adenine can form a bidentate base pair with cytosine. However, due to the low basicity of dA (p*K*~a~ = 3.50) the protonated dA--dC base pair is not observed in neutral solution ([@b38]). As the basicity of 7-deazaadenine is significantly increased, such a mispair seems more easily formed between 2′-deoxy-7-deazaadenosine (p*K*~a~ = 5.30) and dC. In order to investigate this property in more detail, the mismatch discrimination of 2′-deoxytubercidin and its derivatives **1d** or **2**--**4** was studied at various pH values.

### Base recognition of compounds **1a, 1d, 2a--d, 3** and **4** towards the four canonical nucleosides under neutral conditions

In a first series of experiments, the base pair discrimination of the nucleosides **1a**, **1d**, **2a**--**d**, **3** and **4** was investigated under neutral conditions. For this, the *T*~m~ values of 12mer duplexes containing these modified nucleosides located opposite to the four canonical constituents were measured. From the data shown in [Table 4](#tbl4){ref-type="table"} it is apparent that 7-deaza-2′-deoxyadenosine (**1a**) generates a strong base pair not only with dT but also with dC (*T*~m~ = 43°C) an dG (45°C). Similar results were found for its 2-amino derivative **2a**. A base pair formed by **1a** or **2a** with dG is not unexpected, as stable dG--dA base pairs have been already detected. Various motifs for dA--dG or 'c^7^A~d~'--dG pairs have been reported previously ([@b39]--[@b42]). The observation of the highly stable base pair of **2a** and dC was already reported by Saito and co-workers ([@b16]) but without giving an explanation for this phenomenon. Our hybridization experiments show that the base pair of **1a** and dC is strong, while the corresponding dA--dC interaction is very weak (*T*~m~ = 43°C versus *T*~m~ = 36°C; [Table 4](#tbl4){ref-type="table"}). Thus, these properties are caused by the replacement of the purine by the pyrrolo\[2,3-*d*\]pyrimidine system and not by the additional 2-amino group. The study on substituted 7-deazaadenine nucleosides provides further proof.

The same hybridization experiments as discussed above were performed with oligonucleotide duplexes containing the halogenated compounds **1d**, **2b**--**d** and **3**. According to [Table 4](#tbl4){ref-type="table"}, one incorporation of **1d** opposite to dC results in a Δ*T*~m~ = −6°C, whereas a decrease of 3°C is observed for one **1a**-dC mismatch. Similar results were found between compounds **2b**--**d** and **2a** (−5°C versus −1°C). This shows that the introduction of 7-halogen substituents improves the base pair discrimination slightly. Nevertheless, a strong base pair is still observed between 7-halogenated nucleosides **1d**, **2b**--**d** and dC. 7-Halogenated nucleosides also form stable mismatches with dG. In the case of the 2-fluorinated nucleoside **3**, a strong base pair with dG was observed as well (*T*~m~ = 45°C), while significant base discrimination towards dC was now occurring (Δ*T*~m~ = −13°C) ([Table 4](#tbl4){ref-type="table"}). A different situation is observed for the 2-amino-7-deazapurine nucleoside **4**. It shows a base discrimination towards dG (Δ*T*~m~ = −10°C) due to the absence of 6-amino group but generates a relatively stable mispair with dC and dA. Inspection of the p*K*~a~ values of the various nucleosides reveals that they are decreasing in the following order: 5.71 (**2a**) \> 5.30 (**1a**) \> 5.08 (**4**) \> 3.50 (dA) \> less than 1.5 (**3**) (Supplementary Data). A similar relationship is found for the *T*~m~ values of duplexes containing dA\*--dC base pairs (dA\*: modified nucleosides): **2a** (46°C) \> **1a** (43°C) \> **4** (41°C) \> dA (36°C) \> **3** (31°C). The Δ*T*~m~ values $\left( \mid T_{\text{m}}^{\text{dA}*–\text{dC}} \right. - \left. T_{\text{m}}^{\text{dA}*–\text{dT}} \mid \right)$ increased in the reverse order: ∣−1°C∣ (**2a**) \< ∣−3°C∣ (**1a**) \< ∣−6°C∣ (**4**) \<∣−12°C∣ (dA) \< ∣−13°C∣ (**3**). This implies a relationship between mispairing and nucleobase protonation. Consequently, the *T*~m~ values of duplexes containing modified dA-residues pairing with dC or dT were measured at various pH values.

### Base discrimination of compounds **1a, 1d, 2a, 2b, 3** and **4** against dC under acidic or alkaline conditions

Duplexes containing the base pairs of **1a**,**d**-dC, **2a**,**b**-dC, **3**-dC and **4**-dC were investigated in buffer solutions at pH values 6.5, 7.0, 8.0 and 9.0. For comparison, the *T*~m~ of the duplexes incorporating the corresponding dA\*--dT base pair were measured under the same conditions. The data are summarized in [Table 5](#tbl5){ref-type="table"}. It is apparent that the stability of the **1a**-dC pair was enhanced under acid conditions (47°C at pH 6.5), while strongly decreased under basic conditions (39°C at pH 8.0 and 35°C at pH 9.0) ([Table 5](#tbl5){ref-type="table"}). [Figure 4](#fig4){ref-type="fig"} clearly shows the relationship between the stability of **1a**-dC base pair and pH value of the buffer solution. Similar results were found for **2a** ([Table 5](#tbl5){ref-type="table"}). When the pH value is 6.5, the duplex with a **2a**-dC pair (49°C) is even more stable than that incorporating a **2a**-dT base pair (48°C).

Similar results as found for non-halogenated nucleosides **1a** or **2a** are observed for 7-halogenated compounds **1d** and **2b**. The stability of duplexes incorporating **1d**-dC or **2b**-dC pairs decreased with increasing pH values: $T_{\text{m}}^{\text{pH}6.5} > T_{\text{m}}^{\text{pH}7.0} > T_{\text{m}}^{\text{pH}8.0} > T_{\text{m}}^{\text{pH}9.0}$. This demonstrates that the 7-deazapurine nucleosides **1a**,**d** and **2a**,**b** show an enhanced base discrimination towards dC under alkaline conditions. This phenomenon can be clearly seen from [Figure 5A--D](#fig5){ref-type="fig"}. It is apparent that compounds **1a**,**d** and **2a**,**b** show much stronger discrimination towards dC under alkaline condition than that in neutral or acidic medium as indicated from the order of −Δ*T*~m~ $\left( {- \Delta T}_{\text{m}}^{\text{pH}6.5} < {- \Delta T}_{\text{m}}^{\text{pH}7.0} < {- \Delta T}_{\text{m}}^{\text{pH}8.0} < {- \Delta T}_{\text{m}}^{\text{pH}9.0} \right)$. The various *T*~m~ values of the corresponding duplexes with **1a, 1d, 2a** or **2b** opposite to dC at various pH values were visualized in the inserted figures, which reflects the destabilizing effect of alkaline buffer solution on 'c^7^A~d~\*'--dC base pair and the stabilizing effect of mild acid conditions. However, when the pH values are in the range of 6.5--9.0, such a behaviour is not observed for the dA--dC or **3**-dC pairs as indicated from the similar Δ*T*~m~ values (∼−13°C) obtained in acidic, neutral or alkaline medium ([Table 5](#tbl5){ref-type="table"} and [Figure 5E](#fig5){ref-type="fig"}, [F](#fig5){ref-type="fig"}).

According to the p*K*~a~ values of the monomeric nucleosides **1a** (5.30) and **2a** (5.71), one might argue that the p*K*~a~ values are too low to cause protonation under neutral or weak alkaline conditions. However, from p*K*~a~ studies on oligonucleotides it is known that the p*K*~a~ values of nucleobases within stacked oligonucleotides can be raised significantly by the attractive force of the phosphodiester backbone for the protons, and by the stabilization caused by hydrogen bonding ([@b17]). In our case, a p*K*~a~ increase of 1--2 p*K* values is likely to occur. Thus, the protonated base pairs are easily formed between the 7-deazapurine nucleosides **1a** or **2a** and dC under neutral conditions when they are as constituents of oligonucleotides. According to the 7-deazapurine structure a protonation in the five-member ring can be excluded. Possible protonation sites are only nitrogen-1 or nitrogen-3 ([Scheme 4](#sch4){ref-type="fig"}). Rosemeyer and Seela ([@b43]) reported that ^15^N-NMR studies on 7-deazaadenine nucleosides show that the protonation site of **1a** is N-1 (**1ap**; [Scheme 4](#sch4){ref-type="fig"}, right). Therefore, the **1a**-dC or **1d**-dC base pairs should form according to bidentate motifs viia,b with nucleosides **1a** or **1d** in the N-1 protonated state ([Figure 6](#fig6){ref-type="fig"}). Similarly, bidentate base pair motifs viiia--d are suggested for **2a**--**d**-dC mispairs ([Figure 6](#fig6){ref-type="fig"}). Our findings are consistent with earlier observations reported by Hunter *et al.* ([@b37]) on a protonated dA--dC base pair (motif ix) existing in the crystal structure. Also, Saito and co-workers have observed that a wobble base pair of 4-amino-6-methoxy-9-(2′-deoxy-β-D-*erythro*-pentofuranosyl)-7*H*-pyrimido\[4,5-*b*\]indole and dC ([@b44]).

The 2-amino-7-deazapurine nucleoside **4** also generates stable base pair with dC under acidic condition (pH 6.5), whereas the stability of **4**-dC base pair is kept in the same range in neutral or basic buffer solution (pH 7.0, 8.0 and 9.0) ([Table 5](#fig5){ref-type="fig"}). This might be due to the formation of different base pair motifs under acid or neutral and basic conditions. The protonated base pair (motif x) is likely to be generated in acid condition, whereas a wobble base pair xi is present in neutral and basic conditions ([Figure 6](#fig6){ref-type="fig"}). In the case of 2-fluoro-7-deazaadenine nucleoside **3** and dA, rather strong base discrimination was observed against dC keeping the *T*~m~ values constant at different pH values (6.5, 7.0, 8.0, 9.0) ([Table 5](#tbl5){ref-type="table"} and [Figure 5E, F](#fig5){ref-type="fig"}). This results from the properties of dA or compound **3** which are not protonated under these conditions, underlined by the low-p*K*~a~ values of dA (3.5) and **3** (\<1.5).

Regarding the capability to form strong base pairs with both dT and dC, the pyrrolo\[2,3-*d*\]pyrimidines described above show similar properties to *N*^6^-methoxyaminopurine and *N*^6^-methoxy-2,6-diaminopurine 2′-deoxyribonucleosides reported by Brown and co-workers ([@b45],[@b46]). In that case, the formation of two tautomeric structures (amino and imino form) induced by the N^6^-methoxy group was discussed. The present study does not rule out the formation of c^7^dA--dC base pairs where 7-deazaadenine nucleosides are in a rare tautomer form. It does not seem necessary, however, to invoke this hypothesis, since the 6-amino group of nucleosides **1a**,**d** and both 2- and 6-amino groups of **2a**--**d** were found in their ^1^H-NMR spectrum as singlets and the number of hydrogens is two according to the integrals of each peak. Furthermore, the structure of compound **2b** was confirmed by the single-crystal X-ray analysis ([@b47]).

CONCLUSION
==========

i.  *Synthesis.* The novel 2-fluoro-7-deazaadenine nucleoside **3** and various 7-deazapurine nucleoside phosphoramidites (**5a**--**d** and **6**) were synthesized and applied to the solid-phase synthesis of oligonucleotides containing 7-deazapurin-2,6-diamine nucleosides **2a**--**d** or 2-fluoro-2′-deoxytubercidin (**3**). From 2-fluorinated phosphoramidite **6**, oligonucleotides incorporating **3** can be selectively prepared when deprotection was carried out in mild conditions (25% aq. NH~3~, room temperature), whereas the deprotection performed at elevated temperature (25% aq. NH~3~, 60°C) leads to the displacement of 2-fluoro group by amino residue giving oligonucleotides containing **2a**.

ii. *Base pair stability.* 7-Halogen substituents introduced in the 7-deazapurine nucleosides (**1d** or **2b**--**d**) stabilize the base pair with dT in both *aps* and *ps* DNA whereas a 2-fluoro group decreases the base pair stability. The 7-halogenated 7-deazapurin-2,6-diamine nucleosides show stronger stabilizing effects on duplex stability than that of 7-halogenated 2′-deoxytubercidin. 7-Deazapurine nucleosides with amino groups in the 6-position (**1a**), in the 2-position (**4**) or in both positions (**2a**) show similar base pair stability when paring with dT.

iii. *Mismatch discrimination.* 7-Deaza-2′-deoxyadenosine (**1a**) as well as its 2-amino derivative **2a** form strong base pairs not only with dT but also with dC. The 7-halogenated nucleosides **1d** or **2b**--**d** show slightly enhanced base pair discrimination compared with the non-functionalized nucleosides **1a** or **2a**. From pH-dependent *T*~m~ measurements it is apparent that the base discrimination of **1a, 2a** as well as of their 7-halogenated derivatives **1d, 2b** towards dC is strongly improved in weakly alkaline medium. As the *T*~m~ increase can be correlated to the p*K*~a~ values of the nucleosides or to the pH values of buffer solution, protonated base pairs are suggested for the interaction of **1a, 2a**, and of the 7-halogenated compounds **1d** or **2b**--**d** with dC. A strong base discrimination against dC was observed for 7-deaza-2-fluoro-2′-deoxyadenosine (**3**) already in neutral medium, which is similar to that of dA (dA = 3.5; c^7^F^7^A~d~ \<1.5). As the strength of the base pairs of compounds **1a, 1d** or **2a**--**d** with dT or dC depends on the pH value, this phenomenon can be used to generate pH-dependent molecular switches.
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![The structures of nucleosides and phosphoramidites.](gkl719s1){#sch1}

![(i) *N,N*-Dimethylformamide dimethylacetal, methanol, 40--50°C, 24 h. (ii) water, 30--40°C, 48 h. (iii) 4,4′-Dimethoxytriphenylmethyl chloride, anhydrous pyridine. (iv) 2-Cyanoethyl-*N*,*N*-diisopropylchlorophosphoramidite, *N*,*N*-diisopropylethylamine, dichloromethane.](gkl719s2){#sch2}

![(i) Aqueous ammonia, dioxane, 100°C. (ii) HF/pyridine, ^t^BuNO~2~, −60 ∼ −50°C. (iii) 2-Deoxy-3,5-di-*O*-(*p*-toluoyl)-α-D-*erythro*-pentofuranosyl chloride ([@b12]), KOH, TDA-1, MeCN. (iv) Methanolic ammonia. (v) *N,N*-Dimethylformamide dimethylacetal, methanol. (vi) 4,4′-Dimethoxytriphenylmethyl chloride, anhydrous pyridine. (vii) 2-Cyanoethyl-*N,N*-diisopropylchlorophosphoramidite, *N,N*-diisopropylethylamine, dichloromethane.](gkl719s3){#sch3}

![Base pair motifs in *aps* DNA.](gkl719f1){#fig1}

![Graphs of the *T*~m~ values against the numbers of **2b** (A) and **2c** (B) incorporations.](gkl719f2){#fig2}

![Base pair motifs in *ps* DNA.](gkl719f3){#fig3}

![*T*~m~ Profiles of 5′-d(TAGG**C**CAATACT)•3′-d(ATCC**1a**GTTATGA) at different pH values. Measured in 0.1 M NaCl, 10 mM MgCl2 and 10 mM sodium cacodylate buffer, with 5 μM single-strand concentration.](gkl719f4){#fig4}

![Graphs showing the mismatch discrimination $\left( - \Delta T_{\text{m}};T_{\text{m}}^{\text{dA}*–\text{dT}} \right. - \left. T_{\text{m}}^{\text{dA}*–\text{dC}} \right)$ of the duplexes 5′-d(TAGG**X**CAATACT)•3′-d(ATCC**Y**GTTATGA) incorporating **1a** (A), **2a** (B), **1d** (C), **2b** (D), **dA** (E) or **3** (F) in the position **Y**, while dC or dT are in the position **X** (data from [Table 5](#tbl5){ref-type="table"}). The inserts shows the *T*~m~ values of the corresponding duplexes with **1a, 1d, 2a, 2b, 3** and **dA** opposite to dC at various pH values.](gkl719f5){#fig5}

![Protonation of 7-deazaadenine nucleosides.](gkl719s4){#sch4}

![Motifs for mispairs with dC.](gkl719f6){#fig6}

###### 

^13^C-NMR chemical shifts (δ) of 7-deazapurine 2′-deoxyribonucleosides[^a^](#tblfn1){ref-type="table-fn"}

  Compd[^b^](#tblfn2){ref-type="table-fn"},[^c^](#tblfn3){ref-type="table-fn"}    C(2)[^d^](#tblfn4){ref-type="table-fn"} C(2)   C(4)[^d^](#tblfn4){ref-type="table-fn"} C(6)   C(4a) C(5)   C(5) C(7)   C(6) C(8)   C(7a)[^d^](#tblfn4){ref-type="table-fn"} C(4)   C(1′)   C(2′)                               C(3′)   C(4′)   C(5′)
  ------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ------------ ----------- ----------- ----------------------------------------------- ------- ----------------------------------- ------- ------- -------
  **7a**                                                                          160.8                                          152.3                                          107.9        101.0       121.9       152.1                                           82.3    [e](#tblfn5){ref-type="table-fn"}   71.1    87.1    62.1
  **7b**                                                                          160.8                                          152.7                                          104.0        105.1       118.9       151.1                                           82.0    [e](#tblfn5){ref-type="table-fn"}   70.8    87.2    61.7
  **7c**                                                                          160.7                                          152.6                                          105.1        89.4        121.4       151.4                                           82.1    [e](#tblfn5){ref-type="table-fn"}   70.9    87.2    61.8
  **7d**                                                                          160.6                                          152.3                                          106.9        54.4        126.8       151.8                                           82.3    40.4                                70.9    87.2    61.9
  **8a**                                                                          160.9                                          152.4                                          108.0        101.1       121.8       152.3                                           82.4    [e](#tblfn5){ref-type="table-fn"}   71.0    85.5    64.4
  **8b**                                                                          160.9                                          152.8                                          104.2        105.2       118.9       151.1                                           82.1    [e](#tblfn5){ref-type="table-fn"}   70.6    85.4    64.2
  **8c**                                                                          160.9                                          152.7                                          105.3        89.6        121.4       151.5                                           82.3    40.5                                70.7    85.4    64.2
  **8d**                                                                          160.7                                          152.5                                          107.2        54.8        126.7       151.9                                           82.4    [e](#tblfn5){ref-type="table-fn"}   70.8    85.6    64.3
  **1a**                                                                          151.3                                          157.3                                          102.8        99.4        121.4       149.5                                           83.2    39.6                                70.9    81.7    62.0
  **3[^g^](#tblfn7){ref-type="table-fn"}**                                        160.0                                          160.2                                          101.5        101.3       122.4       151.6                                           83.7    [e](#tblfn5){ref-type="table-fn"}   71.8    88.1    62.8
  (J~C,F~)                                                                        199.6                                          20.2                                           3.6                                  18.8                                                                                                        
  **11**[^g^](#tblfn7){ref-type="table-fn"}                                       159.3                                          159.2                                          100.2        99.6        121.0       151.5                                                                                                       
  (J~C,F~)                                                                        197.5                                          20.4                                           3.3                      2.3         19.1                                                                                                        
  **13**[^f^](#tblfn6){ref-type="table-fn"},[^g^](#tblfn7){ref-type="table-fn"}   159.9                                          158.9                                          101.7        100.3       121.6       152.4                                           84.2    38.5                                75.5    82.6    64.8
  (J~C,F~)                                                                        206.1                                          19.0                                           3.8                                  17.6                                                                                                        
  **14**[^g^](#tblfn7){ref-type="table-fn"}                                       158.6                                          162.5                                          109.1        100.4       123.5       152.3                                           82.9    [e](#tblfn5){ref-type="table-fn"}   71.0    87.3    62.0
  (J~C,F~)                                                                        203.6                                          14.6                                           3.1                      3.2         18.3                                                                                                        
  **15**[^g^](#tblfn7){ref-type="table-fn"}                                       159.4                                          163.4                                          110.0        101.9       124.2       153.2                                           83.6    [e](#tblfn5){ref-type="table-fn"}   71.6    86.3    65.0
  (J~C,F~)                                                                        200.2                                          14.4                                           4.7                                  18.3                                                                                                        

^a^Measured in DMSO-*d*~6~.

^b^First heading row = systematic numbering.

^c^Second heading row = purine numbering.

^d^Tentative.

^e^Superimposed by DMSO.

^f^Measured in CDCl~3~.

^g^The second row shows the J~C,F~ coupling constants.

###### 

*T*~m~ values and thermodynamic data of oligonucleotide duplexes containing **1a**, **1d**, **2a**--**d**, **3** and **4** opposite to dT[^a^](#tblfn8){ref-type="table-fn"}

  Duplex                                        *T*~m~ (°C)   $$ (°C)   $\Delta G_{310}^{0}$ (kcal/mol)
  --------------------------------------------- ------------- --------- ---------------------------------
  5′-d(TAGGTCAATACT7) **(16)**                  47                      −10.9
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGGTC**1a**ATACT) **(18)**              46            −1        −10.5
  3′-d(ATCCAG TTATGA) **(17)**                                          
  5′-d(TAGG T CAATACT) **(16)**                 46            −0.5      −10.6
  3′-d(ATCC**1a**GTT**1a**TGA) **(19)**                                 
  5′-d(TAGGTC**1d**ATACT) **(20)**              48            +1.0      −11
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGG T CAATACT) **(16)**                 50            +1.5      −11.3
  3′-d(ATCC**1d**GTT**1d**TGA) **(21)**                                 
  5′-d(TAGG TC**1d**ATACT) **(20)**             51            +1.3      −11.7
  3′-d(ATCC**1d**GTT**1d**TGA) **(21)**                                 
  5′-d(TAGGTC**2a**ATACT) **(22)**              47            0         −10.8
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGGTCAATACT) **(16)**                   47            0         −10.7
  3′-d(ATCC**2a**GTT**2a**TGA) **(23)**                                 
  5′-d(TAGG TC**2a**ATACT) **(22)**             47            0         −10.4
  3′-d(ATCC**2a**G TT**2a**TGA) **(23)**                                
  5′-d(TAGGTCAATACT) **(16)**                   47            0         −10.8
  3′-d(ATCC**2a**GTTATGA) **(24)**                                      
  5′-d(TAGGTC**2b**ATACT) **(25)**              50            +3.0      −11.4
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGGTC**2b2b**TACT) **(26)**             53            +3.0      −12.3
  3′-d(ATCCAG T T ATGA) **(17)**                                        
  5′-d(TAGG TCAATACT) **(16)**                  53            +3.0      −12.4
  3′-d(ATCC**2b**GTT**2b**TGA) **(27)**                                 
  5′-d(TAGG TC**2b**AT ACT) **(25)**            55            +2.7      −12.9
  3′-d(ATCC**2b**GT T**2b**TGA) **(27)**                                
  5′-d(TAGG TC**2b2b**TACT) **(26)**            58            +2.8      −13.7
  3′-d(ATCC**2b**GT T **2b**TGA) **(27)**                               
  5′-d(T**2b**GGTC**2b2b**T**2b**CT) **(28)**   62            +2.5      −14.1
  3′-d(A TCC**2b**GT T **2b**TGA) **(27)**                              
  5′-d(TAGGTC**2c**ATACT) **(29)**              50            +3.0      −11.5
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGGTC**2c2c**TACT) **(30)**             53            +3.0      −12.2
  3′-d(ATCCAG T TATGA) **(17)**                                         
  5′-d(TAGG TCAATACT) **(16)**                  54            +3.5      −12.5
  3′-d(ATCC**2c**GTT**2c**TGA) **(31)**                                 
  5′-d(TAGG TC**2c**ATACT) **(29)**             56            +3.0      −13.4
  3′-d(ATCC**2c**GT T**2c**TGA) **(31)**                                
  5′-d(TAGG TC**2c2c**TACT) **(30)**            58            +2.8      −13.7
  3′-d(ATCC**2c**GT T **2c**TGA) **(31)**                               
  5′-d(T**2c**GGTC**2c2c**T**2c**CT) **(32)**   57            +2.5      −13.5
  3′-d(A TCCAGT T ATGA) **(17)**                                        
  5′-d(T**2c**GGTC**2c2c**T**2c**CT) **(32)**   62            +2.5      −14
  3′-d(ATCC**2c**GT T **2c**TGA) **(31)**                               
  5′-d(TAGGTC**2d**ATACT) **(33)**              50            +3.0      −11.3
  3′-d(ATCCAGTTATGA) **(17)**                                           
  5′-d(TAGG TCAAT ACT) **(16)**                 53            +3.0      −12.4
  3′-d(ATCC**2d**GTT**2d**TGA) **(34)**                                 
  5′-d(TAGG TC**2d**ATACT) **(33)**             54            +2.3      −12.5
  3′-d(ATCC**2d**GTT**2d**TGA) **(34)**                                 
  5′-d(TAGG**T**CAATACT) **(16)**               44            −3        −9.9
  3′-d(ATCC**3**GTTATGA) **(35)**                                       
  5′-d(TAGG**T**CAAT ACT) **(16)**              47            0         −10.9
  3′-d(ATCC**4**GTTATGA) **(36)**                                       

^a^Measured at 260 nm in 0.1 M NaCl, 10 mM MgCl~2~ and 10 mM sodium cacodylate buffer, pH 7.0, with 5 μM single-strand concentration.

^b^*T*~m~ increase per modification.

###### 

*T*~m~ values and thermodynamic data of parallel-stranded oligonucleotides containing **1a, 1d**and **2a**--**d**[^a^](#tblfn10){ref-type="table-fn"}

  Duplex                                                                *T*~m~ (°C)   Δ*T*~m~[^c^](#tblfn12){ref-type="table-fn"}(°C)   Δ*G*^0^~310~ (kcal/mol)
  --------------------------------------------------------------------- ------------- ------------------------------------------------- -------------------------
  5′-d(TiCATAAiCTiGiGAT) **(37)**^b^                                    45                                                              −10.0
  5′-d(AG TATT GA C CTA) **(17)**                                                                                                       
  5′-d(TiCATAAiCTiGiGAT) **(37)**                                       43            −1.0                                              −9.1
  5′-d(AGT**2a**TTG**2a**CCTA) **(23)**                                                                                                 
  5′-d(TiCATAAiCTiGiGAT) **(37)**                                       47            +1.0                                              −10.7
  5′-d(AGT**2b**TTG**2b**CCTA) **(27)**                                                                                                 
  5′-d(TiCATAAiCTiGiGAT) **(37)**                                       47            +1.0                                              −10.7
  5′-d(AGT**2c**TTG**2c**CCTA) **(31)**                                                                                                 
  5′-d(TiCATAAiCTiGiGAT) **(37)**                                       46            +0.5                                              −9.8
  5′-d(AGT**2d**TTG**2d**C CTA) **(34)**                                                                                                
  5′-d(TA GG T CAATACT) **(16)**                                        40                                                              −8.7
  5′-d(ATiCiCAiGTTATiGA) **(38)**[^b^](#tblfn11){ref-type="table-fn"}                                                                   
  5′-d(TAG G T C**2b2b**TACT) **(26)**                                  45            +2.5                                              −9.7
  5′-d(AtiCiCA iGT T ATiGA) **(38)**                                                                                                    
  5′-d(T**2b**GGTC**2b2b**T**2b**CT) **(28)**                           49            +2.3                                              −11.2
  5′-d(ATiCiCAiGTTA TiGA) **(38)**                                                                                                      
  5′-d(TA G GT C**2c2c**TACT) **(30)**                                  45            +2.5                                              −9.7
  5′-d(ATiCiCAiGTTATiGA) **(38)**                                                                                                       
  5′-d(T**2c**GGTC**2c2c**T**2c**CT) **(32)**                           49            +2.3                                              −11.2
  5′-d(ATiCiCAiGTTATiGA) **(38)**                                                                                                       

^a^Measured at 260 nm in 0.1 M NaCl, 10 mM MgCl~2~ and 10 mM sodium cacodylate buffer, pH 7.0, with 5 μM single-strand concentration.

^b^iC~d~ = ^Me^iC~d~= 5-Methyl-2′-deoxyisocytidine; iG~d~ = Cl^7^C^7^iG~d~ = 7-Chloro-7-deaza-2′-deoxyisoguanosine ([@b14]).

^c^*T*~m~ increase per modification.

###### 

*T*~m~ values (°C) of duplexes 5′-d(TAGG**X**CAATACT)**·**3′-d(ATCC**Y**GTTATGA) with mismatches opposite to **1--4**^[a](#tblfn13){ref-type="table-fn"},[b](#tblfn14){ref-type="table-fn"}^

  Y        X                          
  -------- ---- ---------- ---------- ----------
  **A**    48   38 (−10)   46 (−2)    36 (−12)
  **1a**   46   33 (−13)   45 (−1)    43 (−3)
  **2a**   47   36 (−11)   45 (−2)    46 (−1)
  **1d**   48   36(−12)    47 (−1)    41 (−7)
  **2b**   50   39 (−11)   47 (−3)    45 (−5)
  **2c**   50   37 (−13)   46 (−4)    45 (−6)
  **2d**   50   37 (−13)   47 (−3)    45 (−5)
  **3**    44   35 (−11)   45 (+1)    31 (−13)
  **4**    47   40 (−7)    37 (−10)   41 (−6)

^a^Measured at 260 nm in 0.1 M NaCl, 10 mM MgCl~2~ and 10 mM sodium cacodylate buffer, pH 7.0, with 5 μM single-strand concentration.

^b^The data in parentheses are Δ*T*~m~ $\left( T_{\text{m}}^{\text{base\ mismatch}} \right. - \left. T_{\text{m}}^{\text{base\ mismatch}} \right)$.

###### 

*T*~m~ values of oligonucleotide duplex 5′-d(TAGG**X**CAATACT)**·**3′-d(ATCC**Y**GTTATGA) with mismatches opposite to **2a, 2b**, **1a**, **1d, 3** and **4** in different pH values[^a^](#tblfn15){ref-type="table-fn"}

  X·Y        pH 6.5   pH 7.0    pH 8.0   pH 9.0                        
  ---------- -------- --------- -------- --------- ---- --------- ---- ---------
  **T·A**    49                 48                 48             46   
  **C·A**    37       −**12**   35       −**13**   34   −**14**   33   −**13**
  **T·1a**   47                 46                 47             46   
  **C·1a**   47       **0**     43       −**3**    39   −**8**    35   −**11**
  **T·2a**   48                 47                 47             46   
  **C·2a**   49       **+1**    46       −**1**    42   −**5**    37   −**9**
  **T·2b**   52                 50                 51             50   
  **C·2b**   49       −**3**    45       −**5**    43   −**8**    39   −**11**
  **T·1d**   48                 47                 47             45   
  **C·1d**   44       −**4**    41       −**6**    37   −**10**   33   −**12**
  **T·3**    45                 44                 44             43   
  **C·3**    32       −**13**   31       −**13**   31   −**13**   31   −**12**
  **T·4**    47                 47                 47             45   
  **C·4**    44       −**3**    41       −**6**    41   −**6**    39   −**6**

^a^Measured in 0.1 M NaCl, 10 mM MgCl~2~ and 10 mM sodium cacodylate buffer, with 5 μM single-strand concentration.

^b^ ${\Delta T_{\text{m}} = T_{\text{m}}^{\text{dA}*}–\text{dC}} - {T_{\text{m}}^{\text{dA}*}–\text{dT}.}$
